Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Maria V Yusenko"'
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7359 (2024)
It is acknowledged that conventional renal cell carcinoma (cRCC), which makes up 85% of renal malignancies, is a highly vascular tumor. Humanized monoclonal antibodies were developed to inhibit tumor neo-angiogenesis, which is driven by VEGFA/KDR sig
Externí odkaz:
https://doaj.org/article/b8ccb2d6266241ad917dc0180a6350fd
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 35, Iss , Pp 100854- (2023)
Several studies suggested a correlation between cancer associated fibroblasts (CAF) and cancer progression, but data on conventional renal cell carcinoma (cRCC) is still lacking. We aimed to analyse the impact of αSMA positive myo-CAF and FAPα expr
Externí odkaz:
https://doaj.org/article/1dd98fbcdc62412191152d8dc4e0d8ad
Publikováno v:
BBA Advances, Vol 2, Iss , Pp 100034- (2022)
A large body of work has shown that MYB acts as a master transcription regulator in hematopoietic cells and has pinpointed MYB as a potential drug target for acute myeloid leukemia (AML). Here, we have examined the MYB-inhibitory potential of the HDA
Externí odkaz:
https://doaj.org/article/bf2e6bbeff074621b97b1746d59ec016
Publikováno v:
Cells, Vol 11, Iss 7, p 1162 (2022)
Recent studies have disclosed transcription factor MYB as a potential drug target for malignancies that are dependent on deregulated MYB function, including acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC). Although transcription facto
Externí odkaz:
https://doaj.org/article/6db7f5a532f7406e801f03cfa85a2ff0
Autor:
Maria V. Yusenko, Abhiruchi Biyanee, Daria Frank, Leonhard H. F. Köhler, Mattias K. Andersson, Cyrus Khandanpour, Rainer Schobert, Göran Stenman, Bernhard Biersack, Karl-Heinz Klempnauer
Publikováno v:
Cancers, Vol 14, Iss 1, p 43 (2021)
Studies of the role of MYB in human malignancies have highlighted MYB as a potential drug target for acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC). Here, we present the initial characterization of 2-amino-4-(3,4,5-trimethoxyphenyl)-
Externí odkaz:
https://doaj.org/article/874f8c2163b947f4a23a51099bf0d508
Autor:
Luca Abdel Ghani, Maria V. Yusenko, Daria Frank, Ramkumar Moorthy, John C. Widen, Wolfgang Dörner, Cyrus Khandanpour, Daniel A. Harki, Karl-Heinz Klempnauer
Publikováno v:
Cancer Letters. 530:170-180
C/EBPβ has recently emerged as a pro-leukemogenic transcription factor that cooperates with oncoprotein MYB to maintain proliferation and differentiation block of AML cells, making C/EBPβ an interesting drug target for AML. Here we have studied the
Autor:
Amke Trentmann, Debora A. Casolari, Maria V. Yusenko, Henning D. Mootz, Jan-Henrik Mikesch, Karl-Heinz Klempnauer, Mairin Lenz, Maria Francisca Arteaga, Richard J D'Andrea, Wolfgang Dörner, Stefan Klempnauer, Thomas J. Schmidt, Luca Abdel Ghani, Melanie Horn, Carsten Müller-Tidow, Thomas J. Gonda
Publikováno v:
Oncogene
Transcription factor MYB has recently emerged as a promising drug target for the treatment of acute myeloid leukemia (AML). Here, we have characterized a group of natural sesquiterpene lactones (STLs), previously shown to suppress MYB activity, for t
Publikováno v:
Anticancer Research. 40:6863-6867
Background/aim It has been suggested that eosinophilic variant of chromophobe renal cell carcinoma (chRCC) with low chromosome number or lack of genomic alteration has an excellent prognosis in comparison to classic chRCC. The aim of our study was to
Publikováno v:
British Journal of Cancer
Background Approximately 15% of clinically localised conventional renal cell carcinoma (RCC) will develop metastasis within 5 years of follow-up. The aim of this study was to identify biomarkers predicting the postoperative tumour relapse. Methods Ti
Publikováno v:
Anticancer Research. 39:6939-6943
BACKGROUND/AIM In spite of early detection, appoximately 15% of the small renal cell carcinomas (RCC) will develop metastasis within 5 years follow-up. The aim of this study was to identify new biomarkers to estimate the postoperative relapse of the